In the U.S., over 2 million adults over 40 suffer from glaucoma, and whilst it is possible to reduce the visual field loss of this progressive disease with medication, it is vital to go for regular medical check-ups. Non-adherence of sticking to the m…
Vision Problems In Children Born Preterm – What Are The Risk Factors?
Visual impairment in extremely preterm children is mainly due to Retinopathy Of Prematurity (ROP), although cerebral damage, often referred to as cerebral visual impairment, can also be a cause amongst those born extremely premature…
Thiazolidinedione Raises Diabetic Macular Edema
According to a report published Online First in Archives of Internal Medicine, glucose-lowering thiazolidinedione drug therapies in patients with Type 2 diabetes seem to be linked to a higher risk of diabetic macular edema (DME) after 1 and 10-year fo…
Drug Combo Shines for Eye Condition
(MedPage Today) — Two angiogenesis targets are better than one for drug therapy in age-related macular degeneration, results of an industry-sponsored study suggested.
Horizon scanning: Phase II study of FovistaTM and ranibizumab combination vs. ranibizumab monotherapy in wet AMD
Source: BioSpace
Area: News
Ophthotech Corporation has announced results from a prospective, randomised, controlled phase IIb trial of FovistaTM and ranibizumab combination therapy that show statistically significant superior efficacy over ranibizuma…
Ophthotech’s Fovista anti-PDGF combination therapy superior to Lucentis for wet AMD
Ophthotech Corporation today announced results from the first clinical trial to show statistically significant superior efficacy over Lucentis (ranibizumab) monotherapy for the treatment of neovascular age-related macular degeneration (wet AMD).